| Literature DB >> 35027536 |
Xuemei He1,2, Weiqi Hong1, Jingyun Yang1, Hong Lei1, Tianqi Lu1, Cai He1, Zhenfei Bi1, Xiangyu Pan1, Yu Liu1, Lunzhi Dai1, Wei Wang1, Canhua Huang1, Hongxin Deng1, Xiawei Wei3.
Abstract
Entities:
Year: 2022 PMID: 35027536 PMCID: PMC8758697 DOI: 10.1038/s41392-021-00862-3
Source DB: PubMed Journal: Signal Transduct Target Ther ISSN: 2059-3635
Fig. 5PSLs ameliorate ConA-induced ALI and LPS-induced lung injury. a Mice were intravenously injected with 12 mg/kg ConA, followed by treatment with PBS, PCLs, or PSLs. Representative images of liver histopathology with H&E staining in each group. Scale bar represents 200 μm. b–d Quantitative analysis of necrosis area (b), TUNEL-positive cells (c), and serum ALT and AST levels (d) in mice with PBS, PCLs, or PSLs treatment. n = 5. e Survival of 25 mg/kg ConA-injected mice treated with PBS, PCLs, and PSLs. n = 10. f, g The levels of IL-6, IFN-γ, and TNF-α in serum (f) and IL-10, HGF in hepatic tissues (g) were determined by ELISA. n = 3~5 in each group. h Representative images of lung histopathology 72 h after LPS administration. Scale bar represents 200 μm. i Histopathology score of lung sections in each group. n = 5 in each group. Data are represented as mean ± SEM. *p < 0.05, **p < 0.01, ***p < 0.001